Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12

Hoecke, C. Van; Fu, Darrick; Grave, Danny De; Voet, Pierre; Lebacq, E.

doi:10.1016/s0264-410x(98)00052-8

Cited by 11 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Outer surface protein A (OspA) was the first surface protein identified in this bacterium (5,32). The vector-restricted pattern of OspA production was exploited in its development as a transmission-blocking vaccine (24), and in a purified recombinant form, it was the specific immunogenic component of the first Lyme disease vaccine for humans (61,63,66). OspB is the product of a gene cotranscribed with the OspA-encoding gene (31); it is homologous to OspA by inferred amino acid sequence (9) and by structural analysis (7).…”

mentioning

confidence: 99%

Outer Surface Protein A Protects Lyme Disease Spirochetes from Acquired Host Immunity in the Tick Vector

et al. 2008

View full text Add to dashboard Cite

The Lyme disease spirochete Borrelia burgdorferi alters the expression of outer surface protein (osp) genes as the bacterium cycles between ticks and mammals. OspA is produced as borreliae enter the tick vector and remains a major surface antigen during midgut colonization. To elucidate the role of OspA in the vector, we created an insertional deletion of ospA in strain B31-A3. The ospA mutant infects mice when it is injected intradermally and is acquired by larval ticks fed on these mice, where it persists through the molt to the nymph stage. Bacterial survival rates in artificially infected tick larvae fed on naïve mice were compared with those in the vector fed on immune mice. The ospA mutant proliferates in larvae if it is exposed to blood from naïve mice, but it declines in density after larval feeding if the blood is from immune mice. When uninfected larvae are fed on B-cell-deficient mice infected with the ospA mutant, larvae show borrelial densities and persistence that are significantly greater than those fed on infected, immunocompetent mice. We conclude that OspA serves a critical antibody-shielding role during vector blood meal uptake from immune hosts and is not required for persistence in the tick vector.

show abstract

mentioning

confidence: 99%

Outer Surface Protein A Protects Lyme Disease Spirochetes from Acquired Host Immunity in the Tick Vector

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Because of the lack of a direct comparator group in this previous study and the use of a different assay format than those in studies on the same vaccine in seronegative populations (28)(29)(30)(31)(32)(33), it is not clear whether the previous monovalent OspA-1 vaccine induced similar antibody titers in seronegative and seropositive populations.…”

Section: Discussionmentioning

confidence: 89%

A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato

Wressnigg

Barrett

Pöllabauer

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Lyme borreliosis (LB) patients who recover, as well as previously infected asymptomatic individuals, remain vulnerable to reinfection with Borrelia burgdorferi sensu lato. There is limited information available about the use of OspA vaccines in this population. In this study, a randomized double-blind phase I/II trial was performed to investigate the safety and immunogenicity of a novel multivalent OspA vaccine in healthy adults who were either seronegative or seropositive for previous B. burgdorferi sensu lato infection. The participants received three monthly priming immunizations with either 30 g or 60 g alum-adjuvanted OspA antigen and a booster vaccination either 6 months or 9 to 12 months after the first immunization. The antibody responses to the six OspA serotypes included in the vaccine were evaluated. Adverse events were predominantly mild and transient and were similar in the seronegative and seropositive populations. Substantial enzyme-linked immunosorbent assay (ELISA) and surface-binding antibody responses against all six OspA antigens were induced after the primary immunization schedule in both populations, and they were substantially increased with both booster schedules. The antibody responses induced by the two doses were similar in the seronegative population, but there was a significant dose response in the seropositive population. These data indicate that the novel multivalent OspA vaccine is well tolerated and immunogenic in individuals previously infected with B. burgdorferi sensu lato. (This study is registered at ClinicalTrials.gov under registration no. NCT01504347.)

show abstract

“…19,164,165 Vaccines consisting of recombinant OspA (LYMErix; GlaxoSmithKline, New York, NY) were granted approval in the United States in 1998. [166][167][168] They induced the recipient to make anti-Borrelia antibodies that would subsequently be taken into the tick's gut during feeding. Once inside the tick, the antibodies could attack the spirochete, thereby ending the cycle of infection.…”

Section: Vaccinationmentioning

confidence: 99%

Lyme disease

Bhate

Schwartz

2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12

Cited by 11 publications

References 15 publications

Outer Surface Protein A Protects Lyme Disease Spirochetes from Acquired Host Immunity in the Tick Vector

Outer Surface Protein A Protects Lyme Disease Spirochetes from Acquired Host Immunity in the Tick Vector

A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato

Lyme disease

Contact Info

Product

Resources

About